AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15921786 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min test
Number of subjects: 90
Study 15921786 — intervention group
Group type: EXPERIMENTAL
Intervention: All ramp rates
Number of subjects: 90
Study 15921786 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall protocol effect
Number of subjects: 90
Study 11794427 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down therapy with pravastatin (dosing frequency changed from daily to every other day)
Number of subjects: 104
Study 11794427 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-down therapy with pravastatin (daily dose halved)
Number of subjects: 104
Study 10463515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200/100 mg
Number of subjects: 90
Study 10463515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400/200 mg
Number of subjects: 90
Study 10463515 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 800/400 mg
Number of subjects: 90
Study 10463515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 7615103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA) infusion (0.4 micrograms/kg per minute)
Number of subjects: 16
Study 7615103 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study 1696309 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) - two cycles of cisplatin, vindesine, and bleomycin
Number of subjects: 96
Study 1696309 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) - 55 Gy
Number of subjects: 96
Study 870782 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min duration jogging program, 3 days/week
Number of subjects: 157
Study 870782 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min duration jogging program, 3 days/week
Number of subjects: 157
Study 870782 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-min duration jogging program, 3 days/week
Number of subjects: 157
Study 870782 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min duration jogging program, 1 day/week
Number of subjects: 157
Study 870782 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min duration jogging program, 5 days/week
Number of subjects: 157
Study 870782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 31262065 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating competent parents (EC)
Number of subjects: 424
Study 31262065 — intervention group
Group type: EXPERIMENTAL
Intervention: Strivers (n = 151)
Number of subjects: 424
Study 31262065 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrivers (n = 255)
Number of subjects: 424
Study 28597697 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted cough
Number of subjects: 48
Study 28597697 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually assisted cough
Number of subjects: 48
Study 28597697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanically assisted cough
Number of subjects: 48
Study 26618915 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based rehabilitation (CBR) intervention
Number of subjects: 0
Study 23143034 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial working memory task with memory load
Number of subjects: 304
Study 23143034 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory task with memory load
Number of subjects: 304
Study 23143034 — intervention group
Group type: COMPARATOR
Intervention: Visuospatial working memory task without memory load
Number of subjects: 304
Study 23143034 — intervention group
Group type: COMPARATOR
Intervention: Verbal working memory task without memory load
Number of subjects: 304
Study 21623611 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal filter
Number of subjects: 30
Study 18524792 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment for 24 weeks
Number of subjects: 245
Study 18524792 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthesitis score
Number of subjects: 245
Study 18524792 — intervention group
Group type: COMPARATOR
Intervention: Enthesitis presence
Number of subjects: 245
Study 18524792 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver ICC
Number of subjects: 245
Study 16326406 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) with Adriamycin (20 mg/m2), vincristine (1.5 mg/m2), and cisplatin (40 mg/m2) dispersed in 5-10 mL lipiodol, performed 1-3 times.
Number of subjects: 8
Study 16326406 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) with Adriamycin, vincristine, and cisplatin.
Number of subjects: 8
Study 16326406 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) followed by surgery.
Number of subjects: 8
Study 15235875 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction therapy by biweekly phlebotomy for 3 months
Number of subjects: 33
Study 15235875 — intervention group
Group type: COMPARATOR
Intervention: Control group with regular blood tests for 3 months
Number of subjects: 33
Study 11263780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose penicillamine
Number of subjects: 134
Study 11263780 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in HAQ DI score over 2 years
Number of subjects: 134
Study 11263780 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HAQ DI score and total skin score
Number of subjects: 134
Study 11263780 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in HAQ DI score and total skin score over 2 years
Number of subjects: 134
Study 10920881 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 51
Study 10920881 — intervention group
Group type: COMPARATOR
Intervention: Control group (matelin and immune RNA)
Number of subjects: 51
Study 8138886 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering condition
Number of subjects: 60
Study 8138886 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 8138886 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified responses
Number of subjects: 60
Study 3340658 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance training for triceps surae muscles, 24 sessions over 8 weeks
Number of subjects: 28
Study 3340658 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 28
Study 31442783 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychoeducation
Number of subjects: 204
Study 31442783 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based psychoeducation
Number of subjects: 204
Study 31442783 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 28941216 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 1 mg/kg every other week (4 doses)
Number of subjects: 44
Study 28941216 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 0.5, 1.5, or 3 mg/kg weekly (8 doses)
Number of subjects: 44
Study 28941216 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-122 (all doses)
Number of subjects: 44
Study 28941216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27148986 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-Ceramic Fixed Dental Prostheses (MC-FDPs)
Number of subjects: 34
Study 27148986 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Ceramic Fixed Dental Prostheses (AC-FDPs)
Number of subjects: 34
Study 23286311 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of memantine daily
Number of subjects: 70
Study 23286311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21056046 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF Val66Met polymorphism (Val/Met-Met/Met genotype)
Number of subjects: 211
Study 21056046 — intervention group
Group type: COMPARATOR
Intervention: Val/Val genotype
Number of subjects: 211
Study 19154996 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg daily from 20 weeks of pregnancy until delivery)
Number of subjects: 235
Study 19154996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily from 20 weeks of pregnancy until delivery)
Number of subjects: 235
Study 17094031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 68
Study 17094031 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition (WLC)
Number of subjects: 68
Study 15358694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with endobronchial biopsy (EBB) and bronchoalveolar lavage (BAL)
Number of subjects: 159
Study 11704369 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin-coated beStent
Number of subjects: 145
Study 11704369 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 145
Study 9150830 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle plasma level range
Number of subjects: 95
Study 9150830 — intervention group
Group type: COMPARATOR
Intervention: Low plasma level range
Number of subjects: 95
Study 9150830 — intervention group
Group type: COMPARATOR
Intervention: High plasma level range
Number of subjects: 95
Study 7893584 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.25-8 micrograms) and Metoprolol (0.5-8 mg) administered intravenously
Number of subjects: 25
Study 7893584 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 25
Study 3148787 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin alone (group A; n = 8)
Number of subjects: 16
Study 3148787 — intervention group
Group type: COMPARATOR
Intervention: 3.5 mg b.i.d. glibenclamide plus small amounts of intermediate insulin (group B; n = 8)
Number of subjects: 16
Study 29101215 — intervention group
Group type: EXPERIMENTAL
Intervention: Man Up documentary
Number of subjects: 337
Study 29101215 — intervention group
Group type: COMPARATOR
Intervention: Control documentary
Number of subjects: 337
Study 27546885 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off)
Number of subjects: 919
Study 27546885 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off)
Number of subjects: 919
Study 27546885 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off) in patients with ascites
Number of subjects: 919
Study 27546885 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off) in patients with ascites
Number of subjects: 919
Study 24655690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily with low dose ASA
Number of subjects: 21000
Study 24655690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily with low dose ASA
Number of subjects: 21000
Study 24655690 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo with low dose ASA
Number of subjects: 21000
Study 22941233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery
Number of subjects: 47
Study 22941233 — intervention group
Group type: COMPARATOR
Intervention: Conventional pathway
Number of subjects: 47
Study 21121080 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT with standardized birch pollen allergen extract
Number of subjects: 54
Study 21121080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 17101285 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily 24 microg formoterol in the morning
Number of subjects: 321
Study 17101285 — intervention group
Group type: COMPARATOR
Intervention: Twice daily 12 microg formoterol in the morning and evening
Number of subjects: 321
Study 16373887 — intervention group
Group type: EXPERIMENTAL
Intervention: Active titration
Number of subjects: 7893
Study 16373887 — intervention group
Group type: COMPARATOR
Intervention: Usual titration
Number of subjects: 7893
Study 14644833 — intervention group
Group type: EXPERIMENTAL
Intervention: SprayGel adhesion barrier prevention
Number of subjects: 51
Study 14644833 — intervention group
Group type: COMPARATOR
Intervention: Control (no SprayGel)
Number of subjects: 51
Study 14644833 — intervention group
Group type: EXPERIMENTAL
Intervention: SprayGel treatment
Number of subjects: 51
Study 11034574 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5‐aminolaevulinic acid (ALA) 30 mg/kg
Number of subjects: 36
Study 11034574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8836705 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg
Number of subjects: 48
Study 8836705 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg
Number of subjects: 48
Study 8495155 — intervention group
Group type: EXPERIMENTAL
Intervention: 193 mbar treatment in hyperbaric chamber
Number of subjects: 64
Study 8495155 — intervention group
Group type: COMPARATOR
Intervention: 20 mbar control treatment
Number of subjects: 64
Study 8495155 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 64
Study 3549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice with 2.0% zinc chloride
Number of subjects: 0
Study 3549829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29616825 — intervention group
Group type: EXPERIMENTAL
Intervention: High Treatability Information (HTI)
Number of subjects: 309
Study 29616825 — intervention group
Group type: COMPARATOR
Intervention: Low Treatability Information (LTI)
Number of subjects: 309
Study 29616825 — intervention group
Group type: COMPARATOR
Intervention: No Information
Number of subjects: 309
Study 27226183 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation over 90 days
Number of subjects: 102
Study 27226183 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation
Number of subjects: 102
Study 27226183 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 102
Study 27226183 — intervention group
Group type: EXPERIMENTAL
Intervention: RRMS-relapse group
Number of subjects: 102
Study 27226183 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin application
Number of subjects: 102
Study 24746956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash-based reinforcement therapy (CBRT)
Number of subjects: 0
Study 24746956 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based reinforcement therapy (VBRT)
Number of subjects: 0
Study 24746956 — intervention group
Group type: COMPARATOR
Intervention: Non-CM condition
Number of subjects: 0
Study 23842010 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/d by mouth)
Number of subjects: 222
Study 23842010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 20653223 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-color group
Number of subjects: 20
Study 20653223 — intervention group
Group type: COMPARATOR
Intervention: Multicolor group
Number of subjects: 20
Study 17926007 — intervention group
Group type: EXPERIMENTAL
Intervention: RT +/- chemotherapy
Number of subjects: 25
Study 17926007 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 16021014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical cages (VCs)
Number of subjects: 49
Study 16021014 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedged structural allograft (WSA)
Number of subjects: 49
Study 16021014 — intervention group
Group type: EXPERIMENTAL
Intervention: Threaded cylindrical cages (TCCs)
Number of subjects: 49
Study 12963676 — intervention group
Group type: EXPERIMENTAL
Intervention: HUD‐VASH with Section 8 vouchers and intensive case management (n = 182)
Number of subjects: 460
Study 12963676 — intervention group
Group type: COMPARATOR
Intervention: Case management only (n = 90)
Number of subjects: 460
Study 12963676 — intervention group
Group type: COMPARATOR
Intervention: Standard VA care (n = 188)
Number of subjects: 460
Study 10847258 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II receptor blocker), once-daily treatment
Number of subjects: 2673
Study 10847258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2673
Study 8781044 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium mineral water (Ferrarelle, Italy)
Number of subjects: 45
Study 8781044 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium mineral water
Number of subjects: 45
Study 1622873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic antiblastic perfusion (H.A.P.) followed by surgery alone
Number of subjects: 80
Study 1622873 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy including protocol
Number of subjects: 80
Study 4018658 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser vaporization
Number of subjects: 101
Study 4018658 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 101
Study 31738825 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe MGD
Number of subjects: 47
Study 31738825 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MGD
Number of subjects: 47
Study 31738825 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants without MGD)
Number of subjects: 47
Study 29781089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical piperine combined with NB‐UVB
Number of subjects: 63
Study 29781089 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with NB‐UVB
Number of subjects: 63
Study 29781089 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical piperine
Number of subjects: 63
Study 27138110 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program (BWL)
Number of subjects: 49
Study 27138110 — intervention group
Group type: COMPARATOR
Intervention: Emotional Brain Training (EBT)
Number of subjects: 49
Study 24895382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy treatment
Number of subjects: 34
Study 24895382 — intervention group
Group type: COMPARATOR
Intervention: Land-based rehabilitation treatment
Number of subjects: 34
Study 22265384 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapists' assessments using the shoulder classification system
Number of subjects: 255
Study 22265384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern 1 (impingement pain)
Number of subjects: 255
Study 22265384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern 2 (acromioclavicular joint pain)
Number of subjects: 255
Study 22265384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern 3 (shoulder pain: frozen shoulder, glenohumeral arthritis, massive cuff tear, subscapularis tear, painful laxity, post‐traumatic instability, internal derangement)
Number of subjects: 255
Study 20361253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m(2) every 28 days for six cycles
Number of subjects: 155
Study 20361253 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 155
Study 18851754 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention targeting frailty characteristics, functional limitations, nutritional status, falls risk, psychological issues, and management of chronic health conditions.
Number of subjects: 230
Study 18851754 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study 15756577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean IOP during the prospective part of the study
Number of subjects: 90
Study 15756577 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP fluctuations
Number of subjects: 90
Study 15756577 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean IOP level
Number of subjects: 90
Study 11949773 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine 2 mg twice daily
Number of subjects: 19
Study 11949773 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine 4 mg twice daily
Number of subjects: 19
Study 11949773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 19
Study 11949773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11949773 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.05 g/dl)
Number of subjects: 19
Study 10085470 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule A (5 mg MLT)
Number of subjects: 15
Study 10085470 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule B (10 mg MLT)
Number of subjects: 15
Study 10085470 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule C (10 mg MLT)
Number of subjects: 15
Study 7488780 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization
Number of subjects: 0
Study 2206817 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-worn alarm
Number of subjects: 88
Study 2206817 — intervention group
Group type: COMPARATOR
Intervention: Traditional pad and bell alarm
Number of subjects: 88
Study 2206817 — intervention group
Group type: COMPARATOR
Intervention: Modified dry-bed training
Number of subjects: 88
Study 88332 — intervention group
Group type: EXPERIMENTAL
Intervention: subliminal conditioning stimuli applied to the ipsilateral posterior tibial nerve
Number of subjects: 10
Study 88332 — intervention group
Group type: EXPERIMENTAL
Intervention: subliminal conditioning stimuli applied to the contralateral posterior tibial nerve
Number of subjects: 10
Study 30522722 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with ambrisentan and tadalafil
Number of subjects: 500
Study 30522722 — intervention group
Group type: COMPARATOR
Intervention: Pooled monotherapy
Number of subjects: 500
Study 27015912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (3000 IU daily for 12 weeks via oral spray solution)
Number of subjects: 42
Study 27015912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25885424 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic dose adjustment according to the AAD and nonpharmacologic management (fluid and sodium restriction) with four telephone calls over 30 days.
Number of subjects: 135
Study 25885424 — intervention group
Group type: COMPARATOR
Intervention: Standard diuretic dose adjustment by a physician during the first trial visit without telephone follow-up.
Number of subjects: 135
Study 24028546 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks delay between RCT and surgery
Number of subjects: 264